Free Trial

Steven Lichtman Analyst Performance

Managing Director, Senior Research Analyst at Oppenheimer

Steven Lichtman is a stock analyst at Oppenheimer focused in the medical sector, covering 28 publicly traded companies. Over the past year, Steven Lichtman has issued 7 stock ratings, including buy and hold recommendations. While full access to Steven Lichtman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steven Lichtman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
310 Last 11 Years
Buy Recommendations
73.05% 225 Buy Ratings
Companies Covered
28 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy73.1%225 ratings
Hold26.9%83 ratings
Sell0.0%0 ratings

Out of 308 total stock ratings issued by Steven Lichtman at Oppenheimer, the majority (73.1%) have been Buy recommendations, followed by 26.9% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
21 companies
NYSE
21.4% of companies on NYSE
6 companies
OTCMKTS
3.6% of companies on OTCMKTS
1 company

Steven Lichtman, an analyst at Oppenheimer, currently covers 28 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies
85.7%
Miscellaneous
4 companies
14.3%

Steven Lichtman of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
MED PRODUCTS
7 companies
25.0%
MED INSTRUMENTS
6 companies
21.4%
Miscellaneous
4 companies
14.3%
SURGICAL & MEDICAL INSTRUMENTS
3 companies
10.7%
MED/DENTAL - SUPP
2 companies
7.1%
MEDICAL DEVICES
2 companies
7.1%
MED - DRUGS
1 company
3.6%
MED - BIOMED/GENE
1 company
3.6%
SURGICAL APPLIANCES & SUPPLIES
1 company
3.6%
PHARMACEUTICAL PREPARATIONS
1 company
3.6%

Steven Lichtman's Ratings History at Oppenheimer

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Boston Scientific Corporation stock logo
BSX
Boston Scientific
9/8/2025Upgrade$107.14$125.00Outperform
DexCom, Inc. stock logo
DXCM
DexCom
9/8/2025Downgrade$80.51Market Perform
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
9/8/2025Initiated Coverage$12.58$22.00Outperform
Insulet Corporation stock logo
PODD
Insulet
9/8/2025Boost Price Target$345.82$365.00Outperform
DexCom, Inc. stock logo
DXCM
DexCom
7/31/2025Boost Price Target$89.06$102.00Outperform
Boston Scientific Corporation stock logo
BSX
Boston Scientific
7/24/2025Boost Price Target$105.78$118.00Market Perform
Insulet Corporation stock logo
PODD
Insulet
5/9/2025Boost Price Target$310.03$324.00Outperform